GYRE
Price
$6.08
Change
-$0.32 (-5.00%)
Updated
Oct 16 closing price
Capitalization
794.19M
32 days until earnings call
Intraday BUY SELL Signals
SPRC
Price
$1.70
Change
-$0.30 (-15.00%)
Updated
Oct 16 closing price
Capitalization
2.85M
Intraday BUY SELL Signals
Interact to see
Advertisement

GYRE vs SPRC

GYRE vs SPRC Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
GYRE vs. SPRC commentary
Oct 18, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GYRE is a Hold and SPRC is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for GYRE with price predictions
Oct 16, 2026

GYRE in downward trend: price dove below 50-day moving average on October 13, 2026

GYRE moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend. In 42 of 50 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GYRE as a result. In 75 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.

The Moving Average Convergence Divergence Histogram (MACD) for GYRE turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 34 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

The 10-day moving average for GYRE crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for GYRE's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +5.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where GYRE advanced for three days, in 214 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

GYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 133 of 164 cases where GYRE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. GYRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.358) is normal, around the industry mean (26.823). GYRE's P/E Ratio (390.000) is considerably higher than the industry average of (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (6.536) is also within normal values, averaging (438.009).

A.I.Advisor
a Summary for SPRC with price predictions
Oct 16, 2026

Momentum Indicator for SPRC turns negative, indicating new downward trend

SPRC saw its Momentum Indicator move below the 0 level on October 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In 82 of the 89 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for SPRC turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 47 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for SPRC entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +17.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRC advanced for three days, in 150 of 179 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

SPRC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.673) is normal, around the industry mean (26.782). P/E Ratio (0.051) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.682) is also within normal values, averaging (437.542).

The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. SPRC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
GYRE: Fundamental Ratings
GYRE
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
PROFIT vs RISK RATING
1..100
95
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
63
P/E GROWTH RATING
1..100
6
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GYRESPRC
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 13 days ago
83%
Bullish Trend 24 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 18, 2026
Stock price -- (GYRE: $6.08 vs. SPRC: $1.70)
Brand notoriety: GYRE and SPRC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GYRE: 111% vs. SPRC: 69%
Market capitalization -- GYRE: $794.19M vs. SPRC: $2.85M
GYRE [@Biotechnology] is valued at $794.19M. SPRC’s [@Biotechnology] market capitalization is $2.85M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GYRE’s FA Score shows that 1 FA rating(s) are green while SPRC’s FA Score has 2 green FA rating(s).

  • GYRE’s FA Score: 1 green, 4 red.
  • SPRC’s FA Score: 2 green, 3 red.
According to our system of comparison, SPRC is a better buy in the long-term than GYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GYRE’s TA Score shows that 5 TA indicator(s) are bullish while SPRC’s TA Score has 4 bullish TA indicator(s).

  • GYRE’s TA Score: 5 bullish, 5 bearish.
  • SPRC’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both GYRE and SPRC are a good buy in the short-term.

Price Growth

GYRE (@Biotechnology) experienced а -13.64% price change this week, while SPRC (@Biotechnology) price change was -61.97% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.78%. For the same industry, the average monthly price growth was -18.33%, and the average quarterly price growth was -21.56%.

Reported Earning Dates

GYRE is expected to report earnings on Nov 18, 2026.

Industries' Descriptions

@Biotechnology (-10.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
GYRE
Daily Signal:
Gain/Loss:
SPRC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ASRV4.540.08
+1.79%
AmeriServ Financial
COFS33.100.18
+0.55%
ChoiceOne Financial Services
CMND6.440.02
+0.31%
Clearmind Medicine Inc.
AERO15.98-0.37
-2.26%
Grupo Aeromexico S.A.B. De C.V.
AEIS238.05-14.03
-5.57%
Advanced Energy Industries

SPRC and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRC has been loosely correlated with GYRE. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRC jumps, then GYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRC
1D Price
Change %
SPRC100%
-15.00%
GYRE - SPRC
38%
Loosely correlated
-5.00%
TBPH - SPRC
36%
Loosely correlated
N/A
MTNB - SPRC
36%
Loosely correlated
-2.07%
ALZN - SPRC
31%
Poorly correlated
+2.38%
NCEL - SPRC
30%
Poorly correlated
-11.43%
More